Effects of a Botanical Extract on Cognitive Performance and Cerebral Blood Flow in Healthy Adults

November 13, 2026 updated by: Finzelberg GmbH & Co. KG

The Acute Effects of Sideritis Scardica (Greek Mountain Tea) on Cognitive Performance and Cerebral Blood Flow in Healthy Adults

The goal of this clinical trial is to learn how a study product affects cognitive performance and cerebral responses in adults. The study will also collect information about the safety of the study product. Participants will attend a screening visit followed by two study visits. During the study visits, participants will complete computerized cognitive assessments before and after consuming the study product and will wear a NIRS headband to record cerebral responses. Researchers will also monitor participants for adverse events and changes in medications or supplements during the study.

Study Overview

Detailed Description

This clinical trial investigates the acute effects of a Sideritis scardica study product on cognitive performance and cerebral responses during cognitive tasks in adults.

Participants will undergo computerized cognitive assessments together with near infrared spectroscopy (NIRS) recording before and after consumption of the study product. Cognitive testing includes choice reaction time (CRT) and rapid visual information processing (RVIP) tasks. NIRS recording is performed during the assessment periods to characterize cerebral responses associated with cognitive task performance.

Following screening, eligible participants will attend two intervention visits. The first intervention visit represents Day 1, and the second is scheduled approximately 8 days later. At each visit, cognitive and NIRS assessments are performed before study product consumption and are repeated after consumption. Standardized resting NIRS recording periods are incorporated into the assessment sequence.

Adverse events and relevant changes in medical conditions, medications, and supplements will be monitored throughout the study.

Study Type

Interventional

Enrollment (Estimated)

78

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • RLP
      • Andernach, RLP, Germany, 56626
        • Finzelberg
      • Cork, Ireland
        • Atlantia Clinical Trials
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Be able to give written informed consent.
  2. Be between 18-70 years of age.
  3. BMI between 18.5 and 30.0 kg/m2
  4. Willing to refrain from consuming alcohol for 24 h, non-habitual stimulants for 18 h prior to Visit 2 (Day 1) and Visit 3 (Day 8).
  5. Willing and able to comply with all study procedures and consume the study product as instructed at each study visit.

Exclusion Criteria:

  1. Participants who are pregnant or wish to become pregnant during the study or who are lactating and/or currently breastfeeding.

  2. Participants currently of biological childbearing potential but not using a continuous effective method of contraception as determined by the investigator.

  3. Has a history of drug and/or alcohol abuse (within 12 months prior to visit 1)

  4. Participants that are habitual smokers or vapers

  5. High caffeine intake, >400mg/day (approximately equivalent to ≥4 cups of coffee per day

  6. Has food allergies, or other issues with foods, that would preclude intake of the study products.

  7. Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history. Excluded health conditions include:

    1. Uncontrolled hypertension
    2. Clinically significant neurological or mental health conditions (history of stroke/TIA, epilepsy, traumatic brain injury with loss of consciousness, diagnosed ADHD, major depressive disorder within last 6 months)
    3. Diagnosed cognitive impairment
    4. Type I or II diabetes
    5. Clinically significant cardiovascular, liver and renal disease
    6. Diagnosed gastrointestinal conditions (IBD, coeliac disease)
  8. Currently or recently taking a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator. Prohibited medications include:

    a) Prescription medications such a hypnotic, BDZs, antidepressants, antipsychotics, stimulants, beta-blockers, vasodilators, nootropics, and any psychoactive drugs (in the past 2 weeks prior to visit 1)

  9. Current or recent (in the past 2 weeks) use of prohibited nutritional and non-nutritional supplements, that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator, including:

    1. Ginseng, ginkgo biloba, Luteolin, Apigenin supplements
    2. Products containing Sideritis, Sage, Thymus and Oregano
  10. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.

  11. Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study, the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo

Placebo supplement containing carrier material only

Placebo supplement containing carrier material only

Experimental: Siderits

Sideritis supplement administered at an estimated daily dose

Sideritis scardica preparation (Greek Mountain Tea)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference between the Sideritis scardica (Greek Mountain Tea) extract, and placebo in the change from pre-dose assessment to the post-dose assessment period in Cognitive performance (Choice Reaction Time Task x 5 and RVIP x 1)
Time Frame: Baseline, day 1, day 7

Evaluate the acute effects of Greek Mountain Tea extract, compared with placebo on Cognitive performance (Choice Reaction Time Task x 5 and RVIP x 1)

Baseline, day 1, day 7

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognitive performance during the test called Choice Reaction Time (CRT)
Time Frame: Baseline, day 1, day 7

Difference between Sideritis scardica (Greek Mountain Tea) extract and placebo in the change from pre-dose assessment in cognitive performance outcomes of Choice Reaction Time (CRT) with the measurement of following parameters: Choice Reaction Time accuracy, Choice Reaction Time (overall reaction time), Choice Reaction Time (correct response reaction time), Choice Reaction Time Number of Errors (%)

Baseline, day 1, day 7
Cognitive Performance: Rapid Visual Information Processing (RVIP)
Time Frame: Baseline, day 1, day 7

Difference between Sideritis scardica (Greek Mountain Tea) extract and placebo in the change from pre-dose assessment in cognitive performance outcomes of RVIP response time, RVIP false alarms, RVIP Number of Correct Detections (Hits)

Baseline, day 1, day 7
Cerebral total haemoglobin approximately 150 to 240 minutes after administration
Time Frame: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration

Cerebral oxygenation as assessed by near-infrared spectroscopy (NIRS) analysis to determine total haemoglobin.

Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
Cerebral oxygenation
Time Frame: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration

Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis, concurrent changes in tissue saturation index to determine total oxygen saturation.

Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
Cerebral oxygenated haemoglobin (HbO2) approximately 150 to 240 minutes after administration
Time Frame: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration

Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis to determine oxygenated haemoglobin (HbO2) levels.

Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
Cerebral deoxygenated hemoglobin (HHb) approximately 150 to 240 minutes after administration
Time Frame: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration

Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis to determinedeoxygenated hemoglobin (HHb) levels.

Baseline, day 1, day 7, approximately 150 to 240 minutes after administration

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

May 1, 2027

Study Registration Dates

First Submitted

October 30, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • FB_AF216

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The IPD dataset will include de-identified participant-level demographic and baseline characteristics, treatment allocation, and individual results for the primary and secondary outcome measures included in the published analyses. Derived variables necessary to reproduce the reported statistical analyses may also be included. Direct identifiers and other information that could reasonably permit participant identification will not be shared.

IPD Sharing Time Frame

Start date: Following completion of the study and publication of the primary study results.

End date: Available thereafter upon reasonable request, subject to applicable data-retention requirements and sponsor policies.

IPD Sharing Access Criteria

Qualified researchers may request access to de-identified IPD underlying the reported results and relevant supporting documents. Requests must include a scientifically sound proposal and will be reviewed by the study sponsor/data custodian. Approved applicants will receive only the data necessary for the approved purpose through an appropriate secure data-sharing mechanism and, where applicable, under a data-use agreement. No directly identifiable participant information will be shared.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe